Pharmacokinetic and pharmacodynamic bioequivalence between regular human insulin (rDNA origin) in 0.9% sodium chloride ready‐to‐use infusion 1 U/mL and 100 U/mL concentrate diluted to 1 U/mL in healthy males

AIM: To show pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence between Myxredlin, a novel, ready‐to‐use regular human insulin 1 U/mL formulation (BAX‐HI), and Novolin R 100 U/mL concentrate diluted to 1 U/mL (NOVO‐HI). MATERIALS AND METHODS: This phase 1, double‐blind, randomized, two‐way...

Descripción completa

Detalles Bibliográficos
Autores principales: Hompesch, Marcus, Hawryluk, Aleksandra, Hernandez, Moises, Uchil, Beena, Wilmington, Alyssa, Peterson, Lucas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290613/
https://www.ncbi.nlm.nih.gov/pubmed/34378307
http://dx.doi.org/10.1111/dom.14520

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290613/
https://www.ncbi.nlm.nih.gov/pubmed/34378307
http://dx.doi.org/10.1111/dom.14520

Ejemplares similares